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خصائص التهاب الكبد الوبائي ب يف عينة من املرضى العمانيني
خالد النعماين، علي املقبايل، �شهام ال�شنانية
امللخ�ص: الهدف: هدفت الدرا�شة لو�شف اخل�شائ�س الدميوغرافية والفريو�شية لفريو�س التهاب الكبدي الوبائي ب املزمن يف جمموعة من 
املر�شى العمانيني ولتقييم ب�شكل غري مبا�رس فعالية برامج التطعيم �شد فريو�س التهاب الكبدي الوبائي ب وا�شرتاتيجية اللحاق بالتطيعم.
الطرق: درا�شة ا�شتعادية لكل املر�شى اللذين يعانون من التهاب الكبدي الوبائي ب املزمن ومتت معاينتهم وتقييمهم يف عيادة الكبد يف 
م�شت�شفى القوات امل�شلحة، م�شقط، �شلطنة عمان، بني يناير2009 واأبريل 2011. النتائج: �شملت الدرا�شة ما جمموعه 154 مري�شا ا�شتوفوا 
معايري اال�شتمال يف الدرا�شة. كان متو�شط عمر املر�شى امل�شابني 33 �شنة مع ن�شبة %72.7 منهم اأكرب من 27 عاما. �شكلت االإناث ن�شبة 
%47.7 من املر�شى. اأكرث من ن�شف املر�شى مت حتويلهم من عيادتي احلمل والوالدة )%29.2( وبنك الدم )%22.1( يف امل�شت�شفى. 
وجد تاريخ عائلي لالإ�شابة بالتهاب الكبدي الوبائي ب املزمن يف %70 من املر�شى. فح�س املولد امل�شاد ال�شطحي لفريو�س الكبدي 
الوبائي ب )hepatitis B surface antigens( كان اإيجابيا يف ما جمموعه %95 من املر�شى. وجدت امل�شادات اال�شا�شية للفريو�س 
 negative( ب�شكل منفرد يف %5 من املر�شى فقط. كان فح�س مولد امل�شادات اي للفريو�س )hepatitis B core antibodies(
hepatitis B e-antigen( �شلبيا عند معظم املر�شى )%96(. وجد اأن معدل م�شتوى احلم�س النووي للفريو�س كان منخفظا )اأقل من 
2,000 وحدة دولية/مل( يف غالبية املر�شى )%77.9(. لوحظ وجود عالمات تليف الكبد من خالل فحو�شات االأ�شعة يف ن�شبة %5 من 
املر�شى. االأقلية من املر�شى اي ما ن�شبته %9 ا�شتدعت العالج. اخلال�سة: مايقارب من %50 من املر�شى امل�شابني من االإناث، غالبيتهم 
يف �شن االإجناب. يجب على ال�شلطات الطبية يف عمان اأن تدر�س �شيا�شة تطبيق فح�س جميع الن�شاء احلوامل باإ�شتخدام اختبارات التهاب 
الكبدي الوبائي ب يف امل�شل الكاملة. 
مفتاح الكلمات: االلتهاب الكبدي الوبائي ب املزمن؛ لقاحات التهاب الكبد الوبائي ب؛ الوقاية واملكافحة؛ املتربعون بالدم؛ عمان.
abstract: Objectives: This study aimed to describe the demographic and virological characteristics of chronic 
hepatitis B virus (HBV) infection in a sample of Omani patients, and indirectly assess the efficacy of hepatitis B 
vaccination programmes and catch-up strategies. Methods: A retrospective study was undertaken of all patients 
with chronic HBV infections evaluated and followed-up at the Hepatology Clinic of the Armed Forces Hospital 
(AFH), Muscat, Oman, between January 2009 and April 2011. Results: A total of 154 patients met the inclusion 
criteria. The mean age of infected patients was 33 years with 72.7% being over 27 years. Females constituted 
47.7% of the patients. Half of the cohort was referred either from the AFH’s Obstetric Clinic (29.2%) or its Blood 
Bank (22.1%). A family history of chronic HBV infection was present in 70% of patients. A total of 95% had 
positive hepatitis B surface antigens, while only 5% had isolated total hepatitis B core antibodies. Most patients 
(96%) were hepatitis B e-antigen-negative. The majority (77.9%) had low HBV dioribonucleic acid levels of <2,000 
IU/ml. Radiological features of liver cirrhosis were observed in 5%. Patients requiring treatment were in the 
minority (9%). Conclusion: Almost 50% of the infected patients were female, the majority being of childbearing 
age. Medical authorities in Oman should consider enforcing a screening policy for all pregnant women using 
complete hepatitis B serological testing. 
Keywords: Hepatitis B, Chronic; Hepatitis B Vaccines; Hepatitis B, prevention and control; Blood Donors; Oman.
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Advances in Knowledge
- Hepatitis B vaccination has led to a lower prevalence of hepatitis B infection in the younger Omani population as compared to older age 
groups. The postulated vaccination failure rate determined by this study (4%) is in keeping with internationally-documented figures.
- Almost 50% of the infected patients in this study were female, and the majority was of childbearing age. This could lead to a higher 
number of infected children in the future if these potential mothers are not identified by screening and then managed appropriately. 
- Most patients had chronic inactive hepatitis B virus infections while a minority had active infection requiring therapy.
Application to Patient Care
- This study recommends that prevention of hepatitis B virus (HBV) infection be enforced by obligatory antenatal screening of all pregnant 
women, regardless of a history of previous testing or vaccinations, using a complete hepatitis B serology (including hepatitis B core 
antibodies) as the standard of care.
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Despite the introduction of effective vaccinations in 1981, hepatitis B virus (HBV) infection is still a major 
health problem with approximately 350 to 400 
million people infected worldwide.1 A total of 75% of 
those infected live in Asia.2,3 Chronic HBV infection 
is responsible for 60–80% of the cases of liver cancer 
around the world.4 In addition, 25–40% of infected 
patients are expected to die from HBV-related 
complications such as decompensated cirrhosis and 
hepatocellular carcinoma (HCC). This means that 
approximately one million people around the globe 
die each year from HBV infections and related 
complications. This high rate of mortality makes 
chronic HBV infection the ninth leading cause of 
death worldwide.5 
The estimated prevalence of chronic HBV 
infection in Oman is considered to be intermediate 
at 2–7%;6 however, there are no true prevalence 
data to substantiate this figure. Only a few studies 
have been published concerning the prevalence 
of HBV infection in Omani patients— those with 
sickle cell disease and renal disorders requiring 
dialysis or renal transplant—and these studies had 
small sample sizes.7,8 The prevalence of hepatitis B 
among pregnant Omani women in 2006 was found 
to be 7.1%,  with 0.5% being hepatitis B e-antigen 
(e-Ag)-positive.9 
In Oman, hepatitis B vaccinations were carried 
out for all children born in the period from 1984 
to 1990, with a procedure of three serial doses at 0, 
1 and 6 months. The goal of this programme was 
to ensure that by the year 2005 everyone under 21 
years of age would have been vaccinated against 
HBV.10 In addition to the above measures, blood 
bank screening for HBV, using hepatitis B surface 
antigens (HBsAg) as the only marker, was started 
in 1990. In 2009, the screening of all blood units 
using HBsAg as well as hepatitis B core antibodies 
(anti-HBc) was implemented. To date, however, 
routine screening of pregnant women is not yet 
the standard of care in Ministry of Health (MoH) 
institutions.10 
The primary aim of this study was to record 
the descriptive, demographic and virological 
characteristics of chronic HBV mono-infection 
among Omani patients. The secondary aim was an 
indirect assessment of the efficacy of the hepatitis 
B vaccination programmes and the catch-up 
strategies in reducing the prevalence of chronic 
HBV within the age group targeted for vaccination.
Methods
This was a retrospective study based on a review 
of the chart and computer data of all patients with 
chronic HBV infection, who attended and had 
regular follow-up at the Hepatology Clinic of the 
Armed Forces Hospital (AFH), Oman, between 
January 2009 and April 2011. The AFH is one of 
three tertiary hospitals located in the area of the 
capital city, Muscat. Almost one third of the Omani 
population is entitled to receive medical services 
from the AFH. Entitled patients are referred from 
all over Oman, and this study's sample is therefore 
representative of the Omani population. Any 
demographic data missing from the charts and 
computer data review were obtained by telephone. 
Ethical approval for the study was obtained from 
the AFH administration.
The inclusion criteria for the study were all 
Omani patients in the above-specified time period 
who were over 13 years old and had chronic HBV 
infection. Non-Omani patients and patients with 
missing data were excluded, as well as patients co-
infected with hepatitis B and other viruses, such 
as hepatitis C or human immunodeficiency virus 
(HIV). These latter were excluded because co-
infection with HIV and hepatitis C is known to 
change the natural history of hepatitis B. Patients 
co-infected with HIV tend to have a higher rate of 
chronic hepatitis B, a high rate of replication and a 
low rate of HBsAg and e-Ag seroconversion.
A total of 154 patients met the inclusion 
criteria. The following data were collected: patient 
demographic data [Table 1], HBV serology using 
the ARCHITECT i2000SR (Abbott Diagnostics, 
Lake Forest, Illinois, USA) and molecular 
markers using the COBAS® TaqMan® Analyzer 
(Roche Diagnostics International Ltd., Rotkreuz, 
- As 70% of the patients had a positive family history of HBV infection, and bearing in mind that HBV can be transmitted horizontally, 
unvaccinated or non-immune family members should also be vaccinated.
- Patients should be educated that the traditional medical practice of cautery may increase the rate of virus transmission.
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Switzerland) for amplification and detection. It 
has a lower limit of detection of 20 IU/mL and a 
linear dynamic range, with an upper limit of 1.7 × 
108 IU/mL [Table 2]. The markers of liver injury 
(liver enzymes and function) were detected using a 
COBAS® 6000 (C501 Module) Clinical Chemistry 
Analyzer (Roche Diagnostics International Ltd., 
Rotkreuz, Switzerland) and with liver radiological 
investigations. Statistical analysis was performed 
using the Statistical Package for the Social Sciences 
(SPSS) Version 16 (IBM Corp., Chicago, Illinois, 
USA). Data are presented as a mean or, when 
indicated, as an absolute number and a percentage.
Results
A total of 170 patients were initially included in the 
study, with 16 patients subsequently excluded for the 
following reasons: one died, two were co-infected 
with hepatitis C and 13 patients had missing data. 
There were therefore 154 patients included in the 
final analysis. The mean age of the patients was 33 
years, ranging from 13–78 years old. A total of 5 
patients (3.2%) were 13–21 years old, 37 patients 
(24.1%) were 22–27 years old, and 112 patients 
(72.7%) were over 27 years old [Figure 1]. Almost 
half of the patients (47.4%) were female. Half of the 
cohort was referred from obstetric clinics and blood 
banks, reflecting the efficiency of screening certain 
high-risk groups in identifying HBV-infected 
patients. A family history of chronic hepatitis B was 
present in 70% of the patients, with most having 
more than one family member infected with HBV. 
A total of 65% had undergone traditional therapy in 
the form of cautery (wasm in Arabic), which is used 
by Omani healers to treat patients with jaundice. 
This therapy entails applying the tip of a small 
hot rod to certain parts of the body, particularly 
the abdomen and the arms. A total of 40% of the 
females had ear and/or nose piercings that had been 
performed at home or by local dealers using non-
sterile needles. A history of blood transfusions and 
surgeries was present in 15% and 6% of the patients, 
respectively. A total of 95% had positive HBsAg 
while only 5% had isolated total anti-HBc. All of 
the isolated anti-HBc patients (negative HBsAg and 
hepatitis B surface antibodies [anti-HBs]) had a low 
to undetectable viral load. A total of 5 patients had 
Figure 1: The age distribution of the hepatitis 
B-infected Omani patients.
Table 1: Demographic data of the studied patients
Demographic Characteristic N = 154
          n (%)
Age (mean) 33 years 
Gender
    Female 73 (47.4)
    Male 81 (52.6)
referred from
    Obstetric clinics 45 (29.2)
    Blood bank 34 (22.1)
History of
    Family history of hepatitis B 108 (70)
    Traditional cautery (wasm) 100 (65)
    Body piercing(s) 62 (40)
    Blood transfusion(s) 7 (4.5)
    Surgery(ies) 28 (18.2)
Wasm = traditional medicine technique where the tip of a small hot rod 
is applied to certain parts of the body, particularly the abdomen and 
the arms, as a method of treating jaundice.
Table 2: Viral, serological and molecular markers of 
hepatitis B infection
Marker N = 154
                 n (%)
HBsAg and anti-HBc 146 (94.8)




    <2000 IU/ml 120 (77.9)
    2000–20,000 IU/ml 23 (14.9)
    >20,000 IU/ml 11 (7.1)
HBsAg = hepatitis B surface antigen; anti-HBc = hepatitis B core 
antibodies; OBI = occult hepatitis B infection; e-Ag = hepatitis B 
e-antigen; anti-e-Ag = hepatitis B e-antigen antibody; HBV DNA = 
hepatitis B virus dioribonucleic acid.
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a repeatedly undetectable viral load (i.e. <20 IU/
ml) and did not exhibit any rise in HBsAg after one 
dose of the hepatitis B vaccination. One patient had 
a viral load of 80 IU/ml and two patients had viral 
loads from 30–75 IU/ml. The age of these patients 
ranged from 30–60 years old.
Most of our patients (96%) were e-Ag-negative. 
The hepatitis B dioribonucleic acid (HBV DNA) 
level was >20,000 IU/ml in 7%, between 2,000 IU/
ml and 20,000 IU/ml in 15%, and the rest had low 
DNA levels of <2,000 IU/ml. Elevated liver enzymes 
were observed in all DNA level categories and 
radiological features of liver cirrhosis were seen in 
5% of the patients. A minority of our patients (9%) 
required treatment based on international criteria 
and guidelines. 
Discussion
The estimated prevalence of HBV infection in 
Oman is between 2–7%.11,12 The most common 
source of HBV transmission in intermediate- and 
high-prevalence areas is vertical transmutation.13–16 
The majority of the patients in this study were HB 
e-Ag-negative and had a family history of HBV-
infected members. This illustrates that the majority 
of the infections were acquired during the early 
years of life through vertical, peri- or postnatal 
transmission.
The introduction of HBV vaccinations in Taiwan 
in 1984 reduced the rate of HBV infection among 
children from 10% in 1984 to only 1.3% in 1994.17 
The reduction in HBV infection was also associated 
with a reduction in the incidence of HCC.17–19 
The introduction of HBV vaccinations in Oman 
in August 1990, using a procedure of three serial 
doses (at birth, one month and 6 months) as well as 
a catch-up strategy of school campaigns from 2001 
to 2005, has undoubtedly reduced the number of 
new cases of HBV infection in the country.10,20 This 
study revealed that the prevalence of HBV infection 
among those born after 1991 is low (around 4%), 
which is in keeping with the 5–10% expected failure 
rate of HBV vaccinations.21,22 However, the rate of 
infection among those born before the introduction 
of the vaccination, but within the period of the 
catch-up campaigns, is high. This can be partly 
explained by the fact that many of the people 
targeted by the catch-up campaigns received the 
vaccination without being tested to determine 
if they were infected. The other major factor 
contributing to the high rate of infection among this 
group is the length of time the catch-up campaigns 
took to cover the entire country, thus increasing 
the risk of unvaccinated children contracting the 
infection from infected family members. 
The MoH in Oman does not currently support 
a policy of screening pregnant women for viral 
hepatitis.10 However, a substantial percentage of 
our patients (29.2%) were referred from obstetric 
clinics whereas 22.1% were referred from blood 
banks. Jonas et al. demonstrated that if screening 
were only applied to high-risk pregnant women, 
47% of infected women would not have been 
identified.23 Cowan et al. confirmed this and 
showed that screening pregnant women for HBV 
in a low-prevalence area based on identifiable risk 
factors may miss up to 50% of infected pregnant 
women.24 The USA Centers for Disease Control 
and Prevention recommend that the screening of 
pregnant women for hepatitis B be the standard of 
care regardless of previous testing or vaccinations.25 
This screening will identify those patients who 
might need treatment. The benefit of screening 
is not limited to pregnant women, but also helps 
to identify infants who require prophylaxis, and 
other individuals who are in contact with infected 
people and who would also benefit from testing, 
counselling, vaccination and, if indicated, therapy. 
Therefore, we believe that the screening of pregnant 
women in Oman is a necessity.
The prevalence of occult HBV infection (OBI)—
which is defined as the presence of HBV DNA in 
the liver of individuals testing HBsAg-negative with 
currently available assays—varies from one country 
to another. It has been reported to be as low as 
0.56% among blood donors in the UK, and as high 
as 76% among blood donors in Ghana.26 Kaminski 
et al. reported a prevalence of isolated anti-HBc 
(negative HBsAg and negative anti-HBs) to be 2.8% 
among 200 random HBsAg-negative Omani blood 
donor samples.27 
The current study revealed that 5% of patients 
had OBI [Table 2]. The presence of isolated anti-
HBc in a low-endemic area can be due to false-
positive test results.28 However, an isolated anti-
HBc in intermediate to high prevalence areas can 
be due to long-standing infections with a low level 
of replication.29 Several possibilities have been 
suggested to explain the mechanisms of OBI. These 
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include, 1) a surface gene ‘escape’ mutation leading 
to decreased reactivity of the HBsAg detection 
assay;30,31 2) a mutation within the polymerase 
domain that results in a lower production of HBV 
DNA and HBsAg expression;32 3) the formation of 
an HBV-containing immune complex;33 4) altered 
host immune response,34 and 5) co-infection with 
other viruses such as hepatitis C and the hepatitis 
delta virus that may decrease production of HBV 
DNA and increase HBsAg clearance.35–39
Due to the high reported prevalence of OBI 
in intermediate- to high-prevalence areas, the 
screening of high-risk groups should not be 
restricted to HBsAg alone but include total anti-
HBc as well. In 2009, the Central Blood Bank of 
Oman introduced screening for anti-HBc as part 
of the routine screening of blood units for hepatitis 
B. This concept of combining HBsAg with anti-
HBc adds another protective measure against the 
accidental transfusion of infected blood units.
The majority of the patients in this study were 
positive for HBsAg and anti-e-Ag with a low viral 
load, indicating a chronic inactive infection most 
likely acquired during the early years of life. The 
minority had an active HBV infection requiring 
treatment (9%). More than 50% of the patients had 
tried the traditional therapy of wasm before seeking 
medical attention. The belief by patients and 
community in the curative action of this traditional 
therapy has many serious implications. Most of 
the patients who had tried this form of traditional 
therapy believed they were cured and had not 
sought further medical attention until the formal 
screening. Individuals who undergo wasm and do 
not seek further medical advice may present later 
with HBV-related complications such as cirrhosis 
or HCC, and will additionally remain a continuous 
source of HBV infection.
Conclusion
Almost 50% of this study cohort was female 
and the most likely mode of transmission was 
vertical. It is therefore suggested that medical 
authorities in Oman enforce a policy of screening 
all pregnant women, regardless of previous testing 
or vaccinations, using a complete hepatitis B 
serology (including anti-HBc) as the standard of 
care. Transmission through horizontal infection is 
also illustrated in this study, and therefore newborn 
and non-immune family members in contact with 
an infected person must also be vaccinated. 
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